ArticleJournal of cancer education : the official journal of the American Association for Cancer Education2018
Quantitative Information on Oncology Prescription Drug Websites.
Article in Journal of cancer education : the official journal of the American Association for Cancer Education, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.The oncologist · 2023Trial
- FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording.Therapeutic innovation & regulatory science · 2026Article
- Cancer Survivors' and Caregivers' Understanding of FDA Accelerated Approval Disclosures.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Laypersons' understanding of statistical concepts commonly used in prescription drug promotion: A review of the research literature.Research in social & administrative pharmacy : RSAP · 2024Article
- Disclosing accelerated approval on direct-to-consumer prescription drug websites.Pharmacoepidemiology and drug safety · 2018Article
- Cancer treatment in the last 6 months of life: when inaction can outperform action.Ecancermedicalscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Our objective was to determine whether and how quantitative information about drug benefits and risks is presented to consumers and healthcare professionals on cancer-related prescription drug websites. We analyzed the content of 65 active cancer-related prescription drug websites. We assessed the inclusion and presentation of quantitative information for two audiences (consumers and healthcare professionals) and two types of information (drug benefits and risks). Websites were equally likely to present quantitative information for benefits (96.9 %) and risks (95.4 %). However, the amount of the information differed significantly: Both consumer-directed and healthcare-professional-directed webpages were more likely to have quantitative information for every benefit (consumer 38.5 %; healthcare professional 86.1 %) compared with every risk (consumer 3.1 %; healthcare professional 6.2 %). The numeric and graphic presentations also differed by audience and information type. Consumers have access to quantitative information about oncology drugs and, in particular, about the benefits of these drugs. Research has shown that using quantitative information to communicate treatment benefits and risks can increase patients' and physicians' understanding and can aid in treatment decision-making, although some numeric and graphic formats are more useful than others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.